Hyloris Sets Out IPO Terms
Value-Added Medicines Specialist Eyes US 505(b)(2) Opportunities
Value-added medicines specialist Hyloris Pharmaceuticals has set out the financial terms for its IPO, aimed at providing funds to pursue US 505(b)(2) opportunities.
You may also be interested in...
Public Company Edition: Drug developers continue to take advantage of investors’ preference for biotechnology investments, with CRISPR, Acceleron and BioNTech raising massive sums. The wealth isn’t spreading to everyone, however, as DBV Technologies is restructuring and cutting jobs.
Value-added medicines specialist Hyloris Pharmaceuticals is launching an IPO to provide the funds it needs to focus on opportunities through the US 505(b)(2) pathway.
Belgian value-added medicines specialist Hyloris Pharmaceuticals says it has raised €15m through a funding round that will give it the firepower to pursue 505(b)(2) applications in the US.